KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Operations (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Cash from Operations for 17 consecutive years, with 99644000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 46.32% year-over-year to 99644000.0, compared with a TTM value of 827994000.0 through Dec 2025, up 44.54%, and an annual FY2025 reading of 827994000.0, up 44.54% over the prior year.
  • Cash from Operations was 99644000.0 for Q4 2025 at Biomarin Pharmaceutical, down from 368685000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 368685000.0 in Q3 2025 and bottomed at 73932000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 102026600.0, with a median of 98352000.0 recorded in 2021.
  • The sharpest move saw Cash from Operations surged 847.08% in 2021, then plummeted 140.02% in 2022.
  • Year by year, Cash from Operations stood at 11180000.0 in 2021, then tumbled by 39.3% to 6786000.0 in 2022, then surged by 305.0% to 27483000.0 in 2023, then skyrocketed by 575.42% to 185627000.0 in 2024, then plummeted by 46.32% to 99644000.0 in 2025.
  • Business Quant data shows Cash from Operations for BMRN at 99644000.0 in Q4 2025, 368685000.0 in Q3 2025, and 185271000.0 in Q2 2025.